Abstract
Mymensingh district is the most affected area of visceral leishmaniasis (VL) in Bangladesh . Surya Kanta Kala-azar Research Center (SKKRC) was established in 2012 to provide care for patients with VL and post-kala-azar dermal leishmaniasis (PKDL ) and to advance research on associated conditions. We also started a patient registry system to provide short- and long-term follow up for patients given diagnoses of and treated for VL. This chapter demonstrates the baseline characteristics of patients with VL receiving treatment in SKKRC for the first year, from 1st April 2013 to 31st March 2014. We registered 181 patients, consisting of 68 patients with incipient VL and 113 patients with non-incipient VL. Seasonality (more cases in winter and fewer in summer) was observed, mainly for incipient VL. Compared with those with incipient VL, patients with non-incipient VL were more likely to have a family history of PKDL and splenomegaly at physical examination. During the study period, most patients were treated by liposomal amphotericin B (5 mg/day × 3 days). In conclusion, our patient registry system has been successfully established and we will be able to examine the incidence, associated factors, and short- and long-term outcomes of VL treated in SKKRC.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671.
Chowdhury R, Mondal D, Chowdhury V, et al. How far are we from visceral leishmaniasis elimination in Bangladesh? An assessment of epidemiological surveillance data. PLoS Negl Trop Dis. 2014;8:e3020.
SATREPS project kala-azar research center officially opens in Bangladesh—Japan-Bangladesh collaboration contributes to elimination of visceral leishmaniasis. Japan Science and Technology Agency. http://www.jst.go.jp/report/2012/130121_e.html. Accessed 1 Oct 2015.
Epidemiology of Kala-azar (visceral leishmaniasis) and Post-kala-azar dermal leishmaniasis in Bangladesh—a prospective cohort study—‘, UMIN clinical trials registry. https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000013374&language=J. Accessed 1 Oct 2015.
Regional strategic framework for elimination of kala-azar from the South-East Asia Region (2011–2015). WHO regional office for South-East Asia. http://apps.searo.who.int/pds_docs/B4870.pdf?ua=1. Accessed 1 Oct 2015.
Lucero E, Collin SM, Gomes S, et al. Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh. PLoS Negl Trop Dis. 2015;9:e0003699.
Mondal D, Alvar J, Hasnain MG, et al. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. Lancet Glob Health. 2014;2:e51–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing
About this chapter
Cite this chapter
Iwagami, M., Tojo, B., Noiri, E. (2016). Characteristics of Patients Visiting Suruya Kanta Kala-Azar Research Center in Mymensingh, Bangladesh; Data from a Patient Registry System. In: Noiri, E., Jha, T. (eds) Kala Azar in South Asia. Springer, Cham. https://doi.org/10.1007/978-3-319-47101-3_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-47101-3_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43611-1
Online ISBN: 978-3-319-47101-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)